NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis → Alert: Your Bank is Dying – Act Now or Lose Everything! (From Priority Gold) (Ad) Free MRVI Stock Alerts $8.67 -0.22 (-2.47%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$8.59▼$9.1150-Day Range$7.30▼$11.3452-Week Range$4.52▼$14.88Volume2.17 million shsAverage Volume2.01 million shsMarket Capitalization$2.18 billionP/E RatioN/ADividend YieldN/APrice Target$11.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Maravai LifeSciences alerts: Email Address Maravai LifeSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside32.0% Upside$11.44 Price TargetShort InterestHealthy6.23% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.68Based on 12 Articles This WeekInsider TradingSelling Shares$97.52 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.15) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector150th out of 924 stocksPharmaceutical Preparations Industry56th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 2 research reports in the past 90 days.Read more about Maravai LifeSciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.23% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently decreased by 5.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 2.6 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.Search Interest7 people have searched for MRVI on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $97,520,955.00 in company stock.Percentage Held by InsidersOnly 0.63% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.15) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -8.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -8.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Maravai LifeSciences Stock (NASDAQ:MRVI)Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More MRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Stock News HeadlinesMay 31 at 8:42 AM | insidertrades.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Director Sells $97,520,954.94 in StockJune 1 at 4:10 AM | americanbankingnews.comGtcr Investment Xi Llc Sells 9,940,974 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) StockMay 31 at 7:36 AM | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Shares Gap Down to $10.78May 30 at 2:30 AM | americanbankingnews.comStock Traders Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)May 29, 2024 | msn.comSemler Scientific, Genetic Technologies, ReShape Lifesciences among healthcare moversMay 29, 2024 | benzinga.comWhy Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionMay 29, 2024 | marketwatch.comMaravai LifeSciences Shares Fall 16% After Stock-Sale ProposalsMay 19, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (MRVI)May 13, 2024 | businesswire.comTriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation CenterMay 10, 2024 | finance.yahoo.comMaravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 9, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | globenewswire.comMaravai LifeSciences Announces May and June 2024 Investor Conference ScheduleMay 9, 2024 | finance.yahoo.comMaravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights:May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)May 8, 2024 | msn.comMRVI Stock Earnings: Maravai LifeSciences Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | seekingalpha.comMaravai LifeSciences Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | globenewswire.comMaravai LifeSciences Reports First Quarter 2024 Financial ResultsApril 30, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)April 30, 2024 | businesswire.comTriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping TechnologyApril 18, 2024 | businesswire.comTriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance ProductionApril 17, 2024 | msn.comMaravai LifeSciences Holdings (MRVI) Price Target Increased by 6.78% to 9.98April 10, 2024 | globenewswire.comMaravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024March 19, 2024 | finance.yahoo.comShould You Sell Maravai LifeSciences (MRVI)?March 12, 2024 | finance.yahoo.comMRVI Apr 2024 2.500 callMarch 12, 2024 | globenewswire.comMaravai LifeSciences Announces March 2024 Investor Conference ScheduleSee More Headlines Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/02/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees650Year FoundedN/APrice Target and Rating Average Stock Price Target$11.44 High Stock Price Target$17.00 Low Stock Price Target$7.00 Potential Upside/Downside+32.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,030,000.00 Net Margins-47.81% Pretax Margin218.84% Return on Equity-4.28% Return on Assets-1.92% Debt Debt-to-Equity Ratio0.71 Current Ratio11.32 Quick Ratio10.47 Sales & Book Value Annual Sales$288.95 million Price / Sales7.56 Cash Flow$0.09 per share Price / Cash Flow91.55 Book Value$3.09 per share Price / Book2.81Miscellaneous Outstanding Shares251,930,000Free Float250,338,000Market Cap$2.18 billion OptionableOptionable Beta0.03 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Carl W. Hull (Age 65)Co-Founder & Executive Chairman Comp: $617.67kMr. William E. Martin III (Age 49)Chief Executive Officer Comp: $987.86kMr. Kevin M. Herde (Age 52)Executive VP & CFO Comp: $548.62kDr. Peter Michael Leddy Ph.D. (Age 61)Executive VP & Chief Administrative Officer Comp: $583.39kMs. Christine Dolan (Age 56)Executive VP & GM of Cygnus Technologies Comp: $536.63kMr. Andrew Burch (Age 55)President of Nucleic Acid Production Comp: $425.15kMs. Debra HartSenior Director of Investor RelationsMr. Kurt Oreshack (Age 43)Executive VP, General Counsel & Secretary Comp: $701.4kMs. Rebecca BuzzeoExecutive VP & Chief Commercial OfficerDr. Kate E. Broderick Ph.D.Chief Innovation OfficerMore ExecutivesKey CompetitorsSarepta TherapeuticsNASDAQ:SRPTCatalentNYSE:CTLTRoivant SciencesNASDAQ:ROIVElanco Animal HealthNYSE:ELANLegend BiotechNASDAQ:LEGNView All CompetitorsInsiders & InstitutionsGtcr Investment Xi LlcSold 9,940,974 sharesTotal: $97.52 M ($9.81/share)California State Teachers Retirement SystemSold 5,991 shares on 5/16/2024Ownership: 0.045%Kennedy Capital Management LLCSold 7,268 shares on 5/16/2024Ownership: 0.039%Bayesian Capital Management LPBought 74,175 shares on 5/16/2024Ownership: 0.030%Jacobs Levy Equity Management Inc.Sold 114,736 shares on 5/16/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions MRVI Stock Analysis - Frequently Asked Questions Should I buy or sell Maravai LifeSciences stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRVI shares. View MRVI analyst ratings or view top-rated stocks. What is Maravai LifeSciences' stock price target for 2024? 10 brokers have issued twelve-month price targets for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $17.00. On average, they anticipate the company's share price to reach $11.44 in the next year. This suggests a possible upside of 32.0% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts. How have MRVI shares performed in 2024? Maravai LifeSciences' stock was trading at $6.55 at the beginning of 2024. Since then, MRVI stock has increased by 32.4% and is now trading at $8.67. View the best growth stocks for 2024 here. When is Maravai LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our MRVI earnings forecast. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The business earned $64.18 million during the quarter, compared to the consensus estimate of $60.84 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 4.28% and a negative net margin of 47.81%. What ETFs hold Maravai LifeSciences' stock? ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Morningstar US Small Growth (MSGR).Royce Quant Small-Cap Quality Value ETF (SQLV). What guidance has Maravai LifeSciences issued on next quarter's earnings? Maravai LifeSciences issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $271.8 million. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional investors include 12 West Capital Management LP (5.25%), Vanguard Group Inc. (3.99%), Bamco Inc. NY (0.84%), Clearbridge Investments LLC (0.32%), Principal Financial Group Inc. (0.16%) and Jennison Associates LLC (0.16%). View institutional ownership trends. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRVI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward PressTrump conviction scandal exposedPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.